NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
Executive Summary
After putting two generics together and then getting the product approved for a new indication, NitroMed priced its new drug above expectations. But will the old-style pricing strategy hold up in a managed care world?
You may also be interested in...
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
AMAG Pharmaceuticals: Enough Irons In The Fire?
Demand for AMAG’s newly launched Feraheme has been robust but a changing reimbursement climate, especially in the dialysis market, complicates the product’s pricing strategy, and puts increased pressure on management to diversify via dealmaking.